| After the Food and Drug Administration issued a safety alert regarding the possibility of an increased risk of death associated with the use of Paclitaxel-coated devices for the treatment of peripheral arterial disease, a new meta analysis published in the journal of the American College of Cardiology suggested, unequivocally, that there was "no correlation between any level of Paclitaxel exposure and mortality."
Plus, Robert A. Vogel, MD, advises caution against "overzealous blood pressure-lowering" in patients with PAD, Dave Fornell of DAIC features the latest PAD stent tech, and a new study identifies a potential tool for PAD risk stratification. |
